World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
28262
World Ranking
12716
National Ranking
6501

Peter F. Thall publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter F. Thall sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 469 publications — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter F. Thall D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter F. Thall sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2015 - Fellow of the American Statistical Association (ASA)

Overview

Peter F. Thall is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple disciplines, primarily focusing on medicine and mathematics, with a significant emphasis on statistics and probability. Their work includes contributions to hematology, oncology, molecular biology, and economics and econometrics.

The scientist's main research topics include:

  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • Acute Myeloid Leukemia Research
  • Advanced Causal Inference Techniques
  • Hematopoietic Stem Cell Transplantation
  • Cancer Genomics and Diagnostics
  • Optimal Experimental Design Methods

Peter F. Thall has published extensively in prominent journals. Frequent publication venues include:

  • Blood
  • Transplantation and Cellular Therapy
  • Biometrics
  • Journal of Clinical Oncology
  • Cancers

Their recent notable papers include:

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors, 2020, New England Journal of Medicine
  • Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial, 2024, Nature Medicine
  • A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients, 2020, Blood Advances
  • Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer, 2020, Science Translational Medicine
  • Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation, 2021, Journal of Clinical Oncology

Frequent co-authors of Peter F. Thall include:

  • Elizabeth J. Shpall
  • Richard E. Champlin
  • Uday Popat
  • Chitra Hosing
  • Yago Nieto

In addition to journal publications, Peter F. Thall has contributed to book literature. One such book is Statistical Remedies for Medical Researchers, published by Springer International Publishing in 2020.

The scientist has been recognized as a Fellow of the American Statistical Association (ASA), awarded in 2015.

Best Publications

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas

    Robert G. Maki;J. Kyle Wathen;Shreyaskumar R. Patel;Dennis A. Priebat

  • Some covariance models for longitudinal count data with overdispersion.

    Peter F. Thall;Stephen C. Vail

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

    Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva

  • Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs

    Peter F. Thall;John D. Cook

  • Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

    Ana M. Aparicio;Andrea L. Harzstark;Paul G. Corn;Sijin Wen;Sijin Wen

  • Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

    E Estey;P Thall;M Andreeff;M Beran

  • Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study

    Lance C. Pagliaro;Dallas L. Williams;Danai Daliani;Michael B. Williams

  • Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

    Peter F. Thall;Richard M. Simon;Elihu H. Estey

  • Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

    Christopher G. Kanakry;Paul V. O'Donnell;Terry Furlong;Marcos J. De Lima

  • Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

    Elihu H. Estey;Peter F. Thall;Sherry Pierce;Jorge Cortes

  • A STRATEGY FOR DOSE-FINDING AND SAFETY MONITORING BASED ON EFFICACY AND ADVERSE OUTCOMES IN PHASE I/II CLINICAL TRIALS

    Peter F. Thall;Kathy E. Russell

  • High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

    Stefan O. Ciurea;Marcos J.G. de Lima;Pedro Cano;Martin Korbling

  • Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy

    Elihu Estey;Peter Thall;Miloslav Beran;Hagop Kantarjian

  • Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer

    Steven Hsesheng Lin;Lu Wang;Bevan Myles;Peter F Thall

  • Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

    Maarouf A. Hammoud;Raymond Sawaya;Weiming Shi;Peter F. Thall

  • Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate

    Christos N. Papandreou;Danai D. Daliani;Peter F. Thall;Shi Ming Tu

  • Practical Bayesian adaptive randomisation in clinical trials

    Peter F. Thall;J. Kyle Wathen

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Partow Kebriaei
Partow Kebriaei The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Xuemei Wang
Xuemei Wang The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center

External Links

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA isn’t the only way to launch a healthcare career. Many students consider online programs and alternative pathways that can offer greater flexibility and affordability. For example, pursuing an online pharmacy degree can lead to excellent job prospects in pharmaceutical care, often with competitive salaries.

Another in-demand field is health data management. Accredited online schools for health information management train students to organize, analyze, and secure sensitive patient data, preparing them for diverse roles in medical administration and technology.

For those interested in administrative careers, medical billing and coding is a rapidly growing field. Prospective students often weigh the medical coding certification cost to make informed decisions about this short-term, career-ready option.

Finally, nursing careers remain a mainstay in healthcare. If becoming a nurse practitioner is your goal, exploring the cheapest online fnp program may provide a cost-effective way to gain advanced clinical skills and help fill the national nurse shortage.

Best Scientists Citing Peter F. Thall

Trending Scientists

Recently Published Articles